Detection and Treatment of Pregnancy Complications Comprising Determining Sialyl Lewis Antigens and Administering hCG

Abstract

Disclosed herein is a method of identifying and/or addressing incipient preeclampsia in a patient-subject by the steps of (a) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a said patient-subject at about 25 weeks of pregnancy or earlier; (b) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a pregnant non-preeclampsia one or more subjects at about 30 weeks of pregnancy or later, wherein said at least one sialyl Lewis antigen assay is for a sialyl Lewis antigen assayed in step (a) is and if more than one subject is assayed, averaging said results; and (c) managing said patient-subject for preeclampsia, if said level of at least one sialyl Lewis antigen of step (a) is at or greater than about 20% above the level of such silalyl Lewis antigen assayed in step (b).

1 . A method of identifying and/or addressing incipient preeclampsia in a patient-subject by the steps of by the steps of
 (a) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a said patient-subject at about 25 weeks of pregnancy or earlier;   (b) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a pregnant non-preeclampsia one or more subjects at about 30 weeks of pregnancy or later, wherein said at least one sialyl Lewis antigen assay is for a sialyl Lewis antigen assayed in step (a) is and if more than one subject is assayed, averaging said results; and   (c) managing said patient-subject for preeclampsia, if said level of at least one sialyl Lewis antigen of step (a) is at or greater than about 20% above the level of such silalyl Lewis antigen assayed in step (b).   
     
     
         2 . The method of  claim 1 , wherein step (a) is performed at about 20 weeks of pregnancy or earlier. 
     
     
         3 . The method of  claim 2 , wherein step (a) is performed at about 10 weeks of pregnancy or earlier. 
     
     
         4 . A method of identifying and/or addressing incipient preeclampsia in a patient-subject by the steps of by the steps of
 (a) performing a bioassay to determine the level of least two or more sialyl Lewis antigens in a said patient-subject at about 25 weeks of pregnancy or earlier;   (b) performing a bioassay to determine the level of at least two or more sialyl Lewis antigens of step (a) in a pregnant non-preeclampsia one or more subjects at about 30 weeks of pregnancy or later, wherein said at least two or more sialyl Lewis antigens is for a sialyl Lewis antigen assayed in step (a) is and if more than one subject is assayed, averaging said results as to each antigen separately;   (c) managing said patient-subject for preeclampsia, if the sum level of at two or more sialyl Lewis antigens of step (a) is at or greater than about 30% above the level of the sum level of silalyl Lewis antigens assayed in step (b).   
     
     
         5 . The method of  claim 4 , wherein three sialyl Lewis antigens are the subject of the bioassay of step (a) and step (b) wherein step (c) comprises managing said patient-subject for preeclampsia, if the sum level of said three sialyl Lewis antigens of step (a) is at or greater than about 50% above the level of the sum level of the sum of the silalyl Lewis antigens levels assayed in step (b). 
     
     
         6 . A method of determining incipient preeclampsia at 20 weeks of pregnancy or earlier by the steps of
 (a) performing a bioassay to determine the level of at least one sialyl Lewis antigen in a female subject with a diagnosis of preeclampsia about 30 weeks of pregnancy or later, said result being a first comparator;   (b) performing a bioassay to determine the level of said at least one sialyl Lewis antigen of stem (a) in a pregnant non-preeclampsia subject at about 30 weeks of pregnancy or later said result being a second comparator;   (c) performing a bioassay to determine the level of sialyl Lewis antigen in a subject being tested for incipient preeclampsia; and,   (d) managing said patient-subject for preeclampsia, if, upon comparing the level of sialyl Lewis antigens of (c) with said first and second comparators, wherein a sialyl Lewis antigen of level closer to the level of (a) than (b) is predictive of incipient preeclampsia